Analyst Update: Etsy, Wayfair, CytRx Corporation

Analysts adjusted their ratings on Etsy Inc (ETSY), Wayfair Inc (W), and CytRx Corporation (CYTR)

Apr 17, 2015 at 11:31 AM
facebook X logo linkedin


Analysts are weighing in today on Wall Street newcomer Etsy Inc (NASDAQ:ETSY), online retailer Wayfair Inc (NYSE:W), and biotech firm CytRx Corporation (NASDAQ:CYTR). Here's a quick look at today's brokerage notes on ETSY, W, and CYTR.

  • The shares of ETSY debuted on the Street yesterday, hitting an intraday high of $35.74 before settling at $29.77 -- 86% north of their IPO price of $16. Today, Etsy Inc is has lost some steam, down 3.3% at $29. Meanwhile, Wedbush reaffirmed both its "neutral" rating and $14 price target on the equity, which represents a 51.7% deficit to current trading levels. Additionally, the brokerage firm said that while it expects Etsy "to enjoy rapid near-term growth rates within its niche as it increases its marketing spend … some questionable seller practices may draw scrutiny, eventually limiting volume growth." Plus, Wedbush opined, ETSY's valuation is now "well beyond the high end of any comparable group."

  • Goldman Sachs lowered its opinion on W to "neutral" from "buy" -- and removed it from its "America's Buy List" -- sending the shares 6.5% lower to $32.30. Technically speaking, Wayfair Inc has been a standout performer in 2015, with the shares up 62.7% year-to-date, in part due to a post-earnings bull gap last month. Accordingly, options traders have been call-skewed in recent weeks -- over the past 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), 7.27 W calls have been bought to open for every put. Elsewhere, short sellers have taken a shine to the security, as a staggering 41.4% of its available float is sold short. It would take these bettors nearly 12 sessions to cover their positions, at average trading volumes.

  • Oppenheimer initiated coverage on CYTR with an "outperform" rating and a $10 price target -- nearly double the shares' current perch -- citing optimism about the firm's experimental cancer drug. At last check, the shares of CytRx Corporation were up 14% to $5.13, bringing their year-to-date advance to 87.2%. In the options pits, short-term speculators have been more call-heavy than usual, as CYTR's Schaeffer's put/call open interest ratio (SOIR) of 0.16 is lower than 78% of all similar readings from the past year. Meanwhile, nearly 30% of the stock's available float is sold short, which would take over 17 sessions to cover, at average trading volumes.
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI